atrial fibrillation and stroke prevention - Continuing Medical ...
atrial fibrillation and stroke prevention - Continuing Medical ...
atrial fibrillation and stroke prevention - Continuing Medical ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Essentials in Primary Care Conference<br />
Wednesday, July 31, 2013<br />
NVAF ASA Trials:<br />
Dubious Stroke Reduction<br />
AFASAK I<br />
SPAF I<br />
EAFT<br />
ESPS II<br />
LASAF<br />
UK-TIA<br />
Relative Risk Reduction (95% CI)<br />
All trials<br />
22% (2%-38%)<br />
Hart et al. Ann Intern Med. 1999;131:492-501.<br />
100 50 0 -50 -100<br />
Favors ASA Favors Placebo<br />
NVAF Warfarin Trials:<br />
Stroke & Mortality Reduction<br />
All cause mortality RRR = 26%<br />
AFASAK<br />
SPAF<br />
BAATAF<br />
CAFA<br />
SPINAF<br />
•N=2900<br />
• mean age 69<br />
•20% > 70 yrs old<br />
EAFT<br />
All Trials 62% (48%-72%)<br />
100% 50% 0 -50% -100%<br />
Favors Warfarin Favors Placebo<br />
Hart et al. Ann Intern Med. 1999;131:492-501.<br />
Jan Basile, MD<br />
Atrial Fibrillation & Stroke Prevention
Change language